Pacira Biosciences Inc
Change company Symbol lookup
Select an option...
PCRX Pacira Biosciences Inc
DGX Quest Diagnostics Inc
MDLZ Mondelez International Inc
FE FirstEnergy Corp
CADE Cadence Bancorp
SCHD Schwab U.S. Dividend Equity ETF™
ARKK ARK Innovation ETF
URANF International Prospect Ventures Ltd
QSR Restaurant Brands International Inc
STAF Staffing 360 Solutions Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Closing Price
$64.45
Day's Change
-0.65 (-1.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
65.76
Day's Low
63.52
Volume
(Below Average)
Volume:
371,997

10-day average volume:
433,619
371,997

Company Profile

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Valuation Ratios

Price/Earnings (TTM)
19.09x
Price/Sales (TTM)
6.40x
Price/Book (MRQ)
4.41x
Price/Cash Flow (TTM)
16.59x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

March 2021
Current Month
7.4M
Previous Month
7.1M
Percent of Float
17.10%
Days to Cover
19.1242 Days

Share Information

PCRX is in a share class of common stock
Float
43.1M
Shares Outstanding
43.9M
Institutions Holding Shares
338
118.37%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • David M. StackChmn.
  • Max ReinhardtPres.
  • Charles A. ReinhartCFO
  • Kristen WilliamsChief Admin.
  • Charles LaranjeiraOther

Address

Insider Trading

During the most recent quarter, 385K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.